|
WO2019006159A1
|
|
Compositions and methods for treating and preventing staphylococcus aureus infections
|
|
US2018230211A1
|
|
Treatment of hidradenitis suppurativa
|
|
CN106456763A
|
|
Compositions and methods for treating and preventing staphylococcus aureus infections
|
|
EP2904010A1
|
|
Treating vascular disease and complications thereof
|
|
US2014086933A1
|
|
Treatment of diabetes
|
|
US2013195877A1
|
|
Treatment of cachexia by targeting interleukin-1 beta
|
|
US2013039921A1
|
|
Treatment of inflammatory skin disease
|
|
RU2622021C2
|
|
Cachexia therapy
|
|
KR20140044905A
|
|
Identifying affinity-matured human antibodies
|
|
KR20190090046A
|
|
Treatment for dermatological pathologies
|
|
MX2013002160A
|
|
Treatment for neoplastic diseases.
|
|
AU2011100597A4
|
|
Diagnosis, treatment, and prevention of vascular disorders using IL-1alpha autoantibodies
|
|
CN102573895A
|
|
Methods, compositions, and kits for reducing anti-antibody responses
|
|
US2011008282A1
|
|
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
SI2285409T1
|
|
Il-1 alpha antibodies
|
|
NZ613942A
|
|
Interleukin-1 alpha antibodies and methods of use
|
|
CN102580086A
|
|
Treatment of cancer with anti-IL-1[alpha] antibodies
|
|
AU2007251239A1
|
|
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
AU2006274698A1
|
|
Diagnosis, treatment, and prevention of vascular disorders using IL-1a autoantibodies
|
